Prerna Saxena
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Prerna Saxena has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Arshi Aquil
Jamia Hamdard, New Delhi, India
1 shared publicationMohd Akhtar
Jamia Hamdard, New Delhi, India
1 shared publicationMohd Aqil
Jamia Hamdard, New Delhi, India
1 shared publicationMohd Mujeeb
Jamia Hamdard, New Delhi, India
1 shared publication- Nazreen Tabassum
Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India – 110062
1 shared publication - Rabnoor Alam
Jamia Hamdard, New Delhi, India
1 shared publication
Latest Publications
- 5 September 2025
- Published by IGI Global Scientific Publishing
- p. 1-32
Current Treatment Modalities Associated With Glioblastoma and Its Merits and Demerits
Glioblastoma multiforme (GBM) is an aggressive primary brain tumor marked by rapid progression, diffuse infiltration, and poor prognosis. Conventional treatments—surgical resection, radiotherapy, and temozolomide chemotherapy—offer limited success due to intratumoral heterogeneity, the blood-brain barrier (BBB), glioma stem-like cells. Novel immunotherapeutic strategies, including immune checkpoint inhibitors, CAR T and CAR-NK cells, dendritic cell vaccines, and oncolytic virotherapy, are under investigation to improve immune-mediated tumor eradication. Tumor-treating fields (TTFs) and targeted molecular therapies show additional promise. This chapter explores the molecular and metabolic landscape of GBM, reviews current and emerging therapies, and underscores the urgent need for integrated, personalized treatment strategies to improve patient outcomes.
- 5 September 2025
- Published by IGI Global Scientific Publishing
- p. 1-32
Current Treatment Modalities Associated With Glioblastoma and Its Merits and Demerits
Glioblastoma multiforme (GBM) is an aggressive primary brain tumor marked by rapid progression, diffuse infiltration, and poor prognosis. Conventional treatments—surgical resection, radiotherapy, and temozolomide chemotherapy—offer limited success due to intratumoral heterogeneity, the blood-brain barrier (BBB), glioma stem-like cells. Novel immunotherapeutic strategies, including immune checkpoint inhibitors, CAR T and CAR-NK cells, dendritic cell vaccines, and oncolytic virotherapy, are under investigation to improve immune-mediated tumor eradication. Tumor-treating fields (TTFs) and targeted molecular therapies show additional promise. This chapter explores the molecular and metabolic landscape of GBM, reviews current and emerging therapies, and underscores the urgent need for integrated, personalized treatment strategies to improve patient outcomes.